TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02245022
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
Study: NCT00778024
Drug: fluoxetine HCL 40 mg capsules
Normalized name: fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04199013
Drug: Fentanyl Citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in Group R will receive subarachnoid injection of 2.5 ml of 0.75% isobaric ropivacaine (18.75 mg) and 0.5 ml normal saline while patients in Group RF will receive subarachnoid injection of 2.5 ml 0.75% of isobaric ropivacaine (18.75 mg) and 0.5 ml fentanyl (25 μg).
Study: NCT01683838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02149108
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00331240
Drug: placebo (artificial tears)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05808192
Drug: Immunosuppressive
Normalized name: Immunosuppressive acidic protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare MS development in patients who achieve to suspend IS drugs after LT and in those who could not suspend.
Study: NCT03368430
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After finishing scaling and root planing (SRP) in the control group, placebo capsule was taken once daily at bedtime for two months.
Study: NCT00183898
Drug: oxaliplatin, capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
Study: NCT02064894
Drug: oral morphine and oral ibuprofen
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
Study: NCT02064894
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ibuprofen combine to a placebo is the active comparator
Study: NCT00806286
Drug: CS7017 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS7017 tablets, strength 0.25 mg, two tablets, two times daily for twenty-five to thirty months
Study: NCT00806286
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching CS-7017 tablets
Study: NCT00179816
Drug: High-Dose Chemotherapy with Tandem PBSC Rescue.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
Study: NCT02455050
Drug: Systane® Gel Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops of Systane® Gel Drops in each eye.
Study: NCT02455050
Drug: Genteal® Lubricant Gel Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
Study: NCT03257514
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo oral drug have the same shape of thiotacid tablet
Study: NCT00631449
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
Study: NCT04505137
Drug: GMA301 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMA301 Injection administered as a single dose of 1500 mg
Study: NCT04505137
Drug: GMA301 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMA301 Injection administered as a single dose of 2000 mg
Study: NCT02161822
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: simvastatin 80mg qd for 5weeks
Study: NCT00237783
Drug: individualized dialysate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
Study: NCT03633734
Drug: Sequential Treatment
Normalized name: TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: One cycle of the treatment lasts for 56 days. Patients will receive chemotherapy based on Nab-paclitaxel Plus Gemcitabine and modified Folfirinox in sequence order. The cycle will repeat until progression or intolerance of toxicity.
Study: NCT01260519
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unfractionated heparin 2000 unites
Study: NCT02043587
Drug: DNR
Normalized name: Do Not Resuscitate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
Study: NCT02043587
Drug: VCR
Normalized name: VCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages \>50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
Study: NCT02043587
Drug: CTX
Normalized name: CTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/m2 IV, days 1 \&15 for subjects \<40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 \& 16 for subjects \< 40 years of age if day 14 bone marrow M2 or M3; Courses 1A \& 2A
Study: NCT02043587
Drug: Liposomal AraC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg intrathecal (IT), on days 1 \& 15 during Courses 1A \& 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
Study: NCT02043587
Drug: LCV
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B \& 2B
Study: NCT02043587
Drug: AraC
Normalized name: Carac
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2,000 mg/m2 IV, days 1-4 during Courses 1C \& 2C
Study: NCT02043587
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
Study: NCT02141425
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02008786
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
Study: NCT02008786
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04645966
Drug: Scheduled Liquid Paracetamol (SLP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SLP administration after primary vaccinations 1 and 2.
Study: NCT04645966
Drug: Therapeutic Liquid Paracetamol (TLP)
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLP administration after primary vaccinations 1 and 2
Study: NCT01020955
Drug: NutropinAq (GH) and Increlex (IGF-I)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
Study: NCT01020955
Drug: NutropinAq and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
Study: NCT04425135
Drug: Pemetrixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2,D1,ivgtt, Q3w.
Study: NCT03272464
Drug: INCB039110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itacitinib may work by stopping your tumor cells from living and growing.
Study: NCT02640092
Drug: [18F]GTP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive \[18F\]GTP1 as per the schedule specified in the arm description.
Study: NCT02730117
Drug: Anti-Bacterial Agents
Normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial agents deemed appropriate by physicians in the ICU
Study: NCT03903809
Drug: ESPO
Normalized name: Espotabs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received ESPO by subcutaneous injection weekly. The starting dose was 6000 IU and was adjusted according to the instruction to maintain a hemoglobin target range of 10.0-12.0 grams per deciliter (g/dL).
Study: NCT01607307
Drug: Oral/enteral placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
Study: NCT02338193
Drug: DAPA/MET XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
Study: NCT02338193
Drug: DAPA
Normalized name: Sedapap
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg dapagliflozin QD for 20-24 weeks
Study: NCT01437943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 1 tablet (0 mg) daily for 180 days.
Study: NCT02310347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03418090
Drug: 129Xe MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluation of pulmonary function
Study: NCT02854592
Drug: rtPA
Normalized name: Sportpac Coldpac
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous thrombolysis with rtPa
Study: NCT00016172
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02650479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 hour IV infusion.
Study: NCT00230074
Drug: TCH346
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02654860
Drug: Paracetamol 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
Study: NCT02654860
Drug: Placebo injection containing Saline solution 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
Study: NCT02036775
Drug: Lasolvan tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Lasolvan tablet 30 mg twice daily for 5 days.
Study: NCT02036775
Drug: Lasolvan prolonged-released capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
Study: NCT02036775
Drug: Lasolvan effervescent tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
Study: NCT00581087
Drug: DHEA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA : 200 mg/day hard gelatine capsule
Study: NCT00581087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment : 200 mg/day hard gelatine capsule
Study: NCT02553083
Drug: doxycycline 200 mg
Normalized name: doxycycline 200 MG
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 200 mg twice daily for 14 days
Study: NCT02553083
Drug: clarythromicin 500 mg
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarythromicin 500 mg twice a day for 10 days
Study: NCT00694746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
Study: NCT01321463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet once daily for 12 weeks
Study: NCT02828241
Drug: DFD-04 Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03040323
Drug: Lumason 60.7Mg Powder for Injection
Normalized name: Lumason 60.7mg Powder for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
Study: NCT03040323
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebos injected prior to ultrasound-guided biopsy
Study: NCT03365011
Drug: Placebo gas for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gaseous mixture (50% nitrogen and 50% oxygen) for 40 minutes duration under anesthesia supervision with monitoring according to standards set by the American Society of Anesthesiologists.
Study: NCT01674127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01193127
Drug: OMS302 Anti-inflammatory Solution
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01193127
Drug: Balanced Salt Solution (BSS) Solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01682616
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
Study: NCT00746720
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
Study: NCT00746720
Drug: Placebo for Etoricoxib 60 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film coated tablet (orally), two tablets once daily, on day one post surgery
Study: NCT00746720
Drug: Etoricoxib 60 mg
Normalized name: etoricoxib 60 MG
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
Study: NCT00746720
Drug: Placebo for Etoricoxib 60 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
Study: NCT00104260
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03543774
Drug: Simvastatin 40mg
Normalized name: SIMVASTATIN 40MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin mono-therapy at the dose of 40 mg/day for 12 months
Study: NCT03543774
Drug: Ezetimibe/simvastatin 10/20 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin combined therapy at the dose of 10/20 mg/day for 12 months
Study: NCT04748523
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.
Study: NCT01080664
Drug: AS703569
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation~Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion~Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:~Number of cycles: until progression or unacceptable toxicity develops
Study: NCT01080664
Drug: AS703569
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.~Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.
Study: NCT00658021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection, twice a day
Study: NCT03543774
Drug: Ezetimibe/simvastatin 10/40 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe/simvastatin combined therapy at the dose of 10/40 mg/day for 12 months
Study: NCT00416702
Drug: QAB149
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03349008
Drug: Diammonium Glycyrrhizinate
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diammonium Glycyrrhizinate for oral after Magnesium Isoglycyrrhizinate Injection treatment with entecavir-based
Study: NCT03349008
Drug: Diammonium Glycyrrhizinate Placebo
Normalized name: glycyrrhizinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diammonium Glycyrrhizinate Enteric-coated Capsules Placebo
Study: NCT01008982
Drug: LimphoStat-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
Study: NCT00309894
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01540773
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A non-active orally administered supplement of the proprietary amino acid derivative
Study: NCT00003638
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03613727
Drug: Intravenous (IV) and oral Vitamin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) vitamin C 50 mg/kg/day divided in 3 doses beginning on posttransplant Day +1 and continuing through Day +14; each dose (16.7 mg/kg) given in 50 mL of 5% dextrose and water over 30 minutes every 8 hours~• After completion of the IV vitamin C doses, oral vitamin C 500 mg twice each day beginning on Day +15 and continuing until Day +180
Study: NCT05944380
Drug: 0,9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL 0.9% normal saline will be injected for the PENG block
Study: NCT00517127
Drug: Hydroxyethylstarch 6% 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
Study: NCT03463473
Drug: 3 mg/kg Q3W MSB2311 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous infusion with concentration from 3 mg/kg (Q3W)
Study: NCT03463473
Drug: 10 mg/kg Q3W MSB2311 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous infusion with concentration from 10 mg/kg (Q3W)
Study: NCT03463473
Drug: 20 mg/kg Q3W MSB2311 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous infusion with concentration from 20 mg/kg (Q3W)
Study: NCT03463473
Drug: 10 mg/kg Q2W MSB2311 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous infusion with concentration from 10 mg/kg (Q2W)
Study: NCT01104779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
Study: NCT00119002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/kg placebo
Study: NCT02537366
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02216513
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline IV for 4 hours for 5 consecutive days
Study: NCT02044406
Drug: BI 1181181, T1
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet, fed
Study: NCT03760003
Drug: ABX464 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 50mg (One capsule of ABX464 50 mg + One capsule of placebo) once daily for 16 weeks
Study: NCT03760003
Drug: ABX464 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 100mg (two capsules of ABX464 50 mg) once daily for 16 weeks
Study: NCT03760003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules of placebo once daily for 16 weeks
Study: NCT00605761
Drug: SB656933
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg treatment
Study: NCT00605761
Drug: SB656933
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg treatment
Study: NCT03849183
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous normal saline injection to increase the first attempt success rate of radial artery cannulation in pediatric patients
Study: NCT00090363
Drug: ZD4054 15 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg oral tablet once daily
Study: NCT00090363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00090363
Drug: ZD4054 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg oral tablet once daily
Study: NCT00228514
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01523457
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Oxaliplatin 85 mg/m2 IV infused over two hours, followed by~* Leucovorin 400 mg/m2 IV over two hours~* Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)~* 5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours~FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:~FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis.
Study: NCT03673657
Drug: Weekly DP chemotherapy concurrent with thoracic radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly docetaxel (25mg/㎡) and nedaplatin (25mg/㎡) concurrent with thoracic radiotherapy
Study: NCT01752543
Drug: Placebo (Dextrose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
Study: NCT02932306
Drug: IDP-121 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-121 lotion will be applied as per the instructions provided by the investigational center staff.